Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8157232 | 0.68 | PTPN7 (0.43) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29608200 | 0.67 | GRIN2D (0.38) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5851196 | 0.67 | GRIN2D (0.38) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6910044 | 0.64 | KDM1A (0.40) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13973267 | 0.64 | KDM1A (0.47) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5616843 | 0.63 | KDM1A (0.39) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL483392 | 0.63 | KDM1A (0.65) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL61049 | 0.61 | PTPN7 (0.38) | KDM1A | |
| SCHEMBL11498914 | 0.60 | CHRNB2 (0.39) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL23463368 | 0.59 | GRIN2D (0.39) | KDM1AGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268015-A1 | COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2025-08-21 | — | — | US | disclosed |
| EP-4265624-A1 | COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | Lg Chem, Ltd. (KR) | 2023-10-25 | — | — | EP | disclosed |
| US-20230320214-A1 | ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANIC COMPOUND | LG CHEM, LTD. (KR) | 2023-10-05 | — | — | US | disclosed |
| EP-4194460-A1 | ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANIC COMPOUND | Lg Chem, Ltd. (KR) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022139525-A1 | ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANIC COMPOUND | 주식회사 엘지화학 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022139513-A1 | COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | 주식회사 엘지화학 | 2022-06-30 | — | — | WO | disclosed |
| EP-2203055-A1 | 1-METHYL NICOTINAMIDE AND DERIVATIVES FOR TREATMENT OF GASTRIC INJURY | Cortria Corporation (US) | 2010-07-07 | — | — | EP | disclosed |
| US-7655653-B2 | Tetrahydrobenzfluorene derivatives | N.V. ORGANON (NL) | 2010-02-02 | — | — | US | disclosed |
| US-7655653-B2 | Tetrahydrobenzfluorene derivatives | N.V. ORGANON (NL) | 2010-02-02 | — | — | US | disclosed |
| US-20090118225-A1 | 1-Methyl Nicotinamide and Derivatives for Treatment of Gastric Injury | CORTRIA CORPORATION (US) | 2009-05-07 | — | — | US | disclosed |
| US-7304155-B2 | Tetrahydrobenzfluorene derivatives | N.V. ORGANON (NL) | 2007-12-04 | — | — | US | disclosed |
| US-20050119264-A1 | Tetrahydrobenzfluorene derivatives | MERCK SHARP & DOHME B.V. (NL) | 2005-06-02 | — | — | US | disclosed |
| US-20050119264-A1 | Tetrahydrobenzfluorene derivatives | MERCK SHARP & DOHME B.V. (NL) | 2005-06-02 | — | — | US | disclosed |
| EP-1458743-A1 | TETRAHYDROBENZFLUORENE DERIVATIVES | Akzo Nobel N.V. (NL) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003053994-A1 | TETRAHYDROBENZFLUORENE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2003-07-03 | — | — | WO | disclosed |
| EP-0832883-B1 | Tetrahydrobenzo(a)fluorene compounds and methods of use | LILLY CO ELI (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-0832883-B1 | Tetrahydrobenzo(a)fluorene compounds and methods of use | LILLY CO ELI (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-0832883-A1 | Tetrahydrobenzo(a)fluorene compounds and methods of use | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0832883-A1 | Tetrahydrobenzo(a)fluorene compounds and methods of use | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0832883-A1 | Tetrahydrobenzo(a)fluorene compounds and methods of use | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118225-A1 | 1-Methyl Nicotinamide and Derivatives for Treatment of Gastric Injury | NNMT, NAMPT, NNT | KDM1A 579/4885GRIN2D 3360/4885GRIN3B 2193/4885 |
| US-20230320214-A1 | ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANIC COMPOUND | CYP1A1, AOX1, CYP1B1 | KDM1A 661/4885GRIN2D 1010/4885GRIN3B 2061/4885 |
| US-20050119264-A1 | Tetrahydrobenzfluorene derivatives | ESR1, ESR2, GPER1 | KDM1A 878/4885GRIN2D 1618/4885GRIN3B 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.